Health · Medical Research · 6 hrs ago
E. coli vaccine shows no protective effect in older adults
An investigational vaccine against common E. coli pathogens was tested in the phase III E.mbrace trial.
The trial involved more than 17,000 participants.
It focused on older adults, who can get infections caused by these bacteria.
The vaccine did not show a protective effect in this group.
That means the trial did not find evidence that it prevented the infections it was designed to target.
The available information does not say what will happen to the vaccine next.
An investigational vaccine targeting Escherichia coli pathogens did not show a protective effect in older adults.
The finding came from the phase III E.mbrace trial.
The trial included more than 17,000 participants, according to the article.
The article was published on October 14, 2026.
- Who
- More than 17,000 trial participants; the article describes the finding as applying to older adults.
- What
- The investigational E. coli vaccine showed no protective effect in the trial.
- When
- The article was published on October 14, 2026; the trial dates are not stated.
- Where
- Not stated.
- Why
- The trial found no protective effect; the reason for the result is not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Vaccine target
- Escherichia coli pathogens
- Trial
- Phase III E.mbrace
- Participants
- More than 17,000
- Article publication
- October 14, 2026